6月7日-14日，全球共达成11项资产授权与合作交易。中国医药市场共达成3项交易，包括2项出海交易和1项国内交易。艾伯维和明济生物之间就后者一临床前资产达成授权交易，首付款1.5亿美元，总金额17.1亿美元。武田制药与亚盛医药签署奥雷巴替尼独家许可选择权协议，总金额13亿美元。丽珠制药与轩竹生物就后者PDE5抑制剂复达那非达成独家授权许可合作。
国际市场上，共签署了8项资产授权与合作交易。其中最值得关注的交易是GSK与Ochre Bio之间签署的多年数据许可协议，总金额3750万美元。
From June 7 to 14, a total of 11 licensing and cooperation deals were signed globally. In the China Biotech Industry, there were 2 out-licensing deal and 1 domestic licensing deal. Futuregen Biopharm signed an out-licensing deal with AbbVie for a pre-clinical stage asset, amounting to a total deal of $1.71 billion, with an upfront payment of $150 million. Ascentage Pharma signed a $1.3 Billion out-licensing agreement with Takeda Pharmaceuticals for Olverembatinib. Meanwhile, Xuanzhu Biopharm and Livzon Pharmaceutical signed a domestic licensing deal for Fadanafil.
Globally, there were 8 other licensing and cooperation deals signed. The highlight deal of the week was the licensing agreement between Ochre Bio and GSK, amounting to a total of $37.5 million.
2b. Global section
3. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit www.yafocapital.com
Event Name: ACCESS CHINA Networking & Gathering @BIO
